Fluorescently labeled bevacizumab in human breast cancer - Defining the classification threshold

Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L.L. Adams, Mariëtte E.G. Kranendonk, A. G.T.T. van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina OliveiraArjen J. Witkamp, Willem P.Th M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G.E. de Vries, Axel Walch, Gooitzen M. van Dam, Vasilis Ntziachristos

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Original languageEnglish
Title of host publicationEuropean Conference on Biomedical Optics, ECBO 2017
PublisherOptica Publishing Group (formerly OSA)
ISBN (Electronic)9781509067367
DOIs
StatePublished - 2017
EventEuropean Conference on Biomedical Optics, ECBO 2017 - Munich, Germany
Duration: 25 Jun 201729 Jun 2017

Publication series

NameOptics InfoBase Conference Papers
VolumePart F61-ECBO 2017
ISSN (Electronic)2162-2701

Conference

ConferenceEuropean Conference on Biomedical Optics, ECBO 2017
Country/TerritoryGermany
CityMunich
Period25/06/1729/06/17

Keywords

  • Clinical applications
  • Imaging systems
  • Medical and biological imaging

Fingerprint

Dive into the research topics of 'Fluorescently labeled bevacizumab in human breast cancer - Defining the classification threshold'. Together they form a unique fingerprint.

Cite this